The metabolism of Olanzapine can be decreased when combined with Fluvoxamine. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Guanfacine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Glutethimide. The metabolism of Olanzapine can be decreased when combined with Darifenacin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cetirizine. The serum concentration of Erlotinib can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Morphine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dextropropoxyphene. The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Eszopiclone. The metabolism of Olanzapine can be decreased when combined with Rolapitant. The risk or severity of adverse effects can be increased when Diazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Prazepam is combined with Olanzapine. Olanzapine can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methapyrilene. The risk or severity of adverse effects can be increased when Methysergide is combined with Olanzapine. The therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Azithromycin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Benperidol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Eltanolone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Triprolidine. The serum concentration of Cefditoren can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Perazine is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Leuprolide. Olanzapine may increase the sedative activities of Rotigotine. Olanzapine may decrease the stimulatory activities of Benzphetamine. The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Olanzapine. The serum concentration of Bosutinib can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Vigabatrin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alfentanil. The risk or severity of adverse effects can be increased when Olanzapine is combined with Thiamylal. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ketazolam. The risk or severity of adverse effects can be increased when Olanzapine is combined with Thiothixene. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dexmedetomidine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorprothixene. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenobarbital. Zimelidine may increase the serotonergic activities of Olanzapine. Brofaromine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Drotebanol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Flibanserin. Olanzapine may increase the QTc-prolonging activities of Domperidone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethylmorphine. The risk or severity of adverse effects can be increased when Alimemazine is combined with Olanzapine. The therapeutic efficacy of Phenformin can be decreased when used in combination with Olanzapine. Olanzapine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fentanyl. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxybuprocaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate. The metabolism of Olanzapine can be decreased when combined with Isoniazid. The serum concentration of Ibrutinib can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Doxepin. Olanzapine may increase the QTc-prolonging activities of Ziprasidone. Olanzapine may decrease the stimulatory activities of MMDA. The risk or severity of adverse effects can be increased when Temazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Flurazepam is combined with Olanzapine. The therapeutic efficacy of Glipizide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Carisoprodol. Olanzapine may increase the sedative activities of Metyrosine. The serum concentration of Cerivastatin can be increased when it is combined with Olanzapine. Olanzapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pomalidomide. The metabolism of Olanzapine can be decreased when combined with Ticlopidine. The serum concentration of Nilotinib can be decreased when it is combined with Olanzapine. Droperidol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Bromazepam is combined with Olanzapine. The serum concentration of Fluvastatin can be increased when it is combined with Olanzapine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Olanzapine may increase the QTc-prolonging activities of Ceritinib. Olanzapine may increase the QTc-prolonging activities of Artemether. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trazodone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Nortriptyline. The risk or severity of adverse effects can be increased when Olanzapine is combined with Difenoxin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Sevoflurane. Olanzapine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Meclizine. The risk or severity of adverse effects can be increased when Sumatriptan is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyproheptadine. The serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Vortioxetine. The metabolism of Olanzapine can be decreased when combined with Clemastine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Aceprometazine. The risk or severity of adverse effects can be increased when Selegiline is combined with Olanzapine. The risk or severity of adverse effects can be increased when Naratriptan is combined with Olanzapine. The therapeutic efficacy of Mesalazine can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when CE-326597 is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Perospirone. Olanzapine may increase the sedative activities of Pramipexole. Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ezogabine. The metabolism of Olanzapine can be decreased when combined with Paroxetine. The therapeutic efficacy of Miglitol can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Clidinium. The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Olanzapine. The serum concentration of Lovastatin can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alfaxalone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Nalbuphine. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Olanzapine. The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Baclofen. The risk or severity of adverse effects can be increased when Olanzapine is combined with Brexpiprazole. The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Hydromorphone is combined with Olanzapine. Olanzapine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Olanzapine is combined with Proparacaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxycodone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Olanzapine is combined with Lofentanil. The serum concentration of Olanzapine can be increased when it is combined with Panobinostat. The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Protriptyline. Venlafaxine may increase the serotonergic activities of Olanzapine. Olanzapine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dezocine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethotoin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chloral hydrate. Olanzapine may increase the QTc-prolonging activities of Ciprofloxacin. The serum concentration of Olanzapine can be increased when it is combined with Ranolazine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Mepivacaine. The risk or severity of adverse effects can be increased when Ergonovine is combined with Olanzapine. Harmaline may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Propoxycaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fencamfamine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ritanserin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dimenhydrinate. The risk or severity of adverse effects can be increased when Pergolide is combined with Olanzapine. The serum concentration of Mevastatin can be increased when it is combined with Olanzapine.